Terns Pharmaceuticals, Inc.
TERNDelisted May 5, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001831363
Terns Pharmaceuticals, Inc. was delisted on May 5, 2026; its insiders filed their last Form 4 on May 5, 2026; 319 institutions reported holding it in 13F filings for Q1 2026, worth $6.56B in total; Soros Fund Management was the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:34 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 9, 2026 | Mar 20, 2025 | Mar 14, 2024 | Mar 27, 2023 | Mar 3, 2022 |
| Revenue | – | – | – | $0 | $1.00M |
| Research and development | $77.9M | $70.1M | $63.5M | $39.6M | $31.3M |
| Selling, general and administrative | $32.2M | $31.8M | $39.1M | $22.4M | $19.5M |
| Operating income | -$110.1M | -$101.9M | -$102.6M | -$62.0M | -$49.9M |
| Income tax | $581.0K | $260.0K | $239.0K | $358.0K | $508.0K |
| Net income | -$96.2M | -$88.9M | -$90.2M | -$60.3M | -$50.2M |
| EPS, basic | $-1.03 | $-1.12 | $-1.27 | $-1.67 | – |
| EPS, diluted | $-1.03 | $-1.12 | $-1.27 | $-1.67 | – |
| Weighted shares, basic | 93.2M | 79.5M | 71.3M | 36.0M | – |
| Weighted shares, diluted | 93.2M | 79.5M | 71.3M | 36.0M | – |
| Margins and growth | |||||
| Operating margin | – | – | – | – | -4986.0% |
| Net margin | – | – | – | – | -5015.8% |
| Revenue growth, year over year | – | – | – | −100.0% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 9, 2026 | Mar 20, 2025 | Mar 14, 2024 | Mar 27, 2023 | Mar 3, 2022 |
| Cash and equivalents | $524.7M | $161.4M | $79.9M | $143.2M | $47.7M |
| Short-term investments | $494.2M | $196.7M | $183.5M | $139.9M | $118.3M |
| Total current assets | $1.02B | $362.1M | $267.4M | $285.2M | $166.9M |
| Property, plant and equipment | $47.0K | $222.0K | $506.0K | $757.0K | $1.05M |
| Total assets | $1.03B | $363.9M | $268.5M | $287.0M | $168.1M |
| Accounts payable | $1.72M | $2.15M | $2.52M | $1.65M | $2.13M |
| Total current liabilities | $16.4M | $15.7M | $11.9M | $8.47M | $6.82M |
| Long-term debt | – | – | $0 | $544.0K | – |
| Total liabilities | $18.6M | $18.1M | $13.2M | $10.1M | $7.77M |
| Shareholders' equity | $1.01B | $345.9M | $255.4M | $276.9M | $160.3M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 9, 2026 | Mar 20, 2025 | Mar 14, 2024 | Mar 27, 2023 | Mar 3, 2022 |
| Operating cash flow | -$82.2M | -$70.0M | -$67.4M | -$49.1M | -$41.8M |
| Capital expenditures | $0 | $42.0K | $52.0K | $275.0K | $340.0K |
| Free cash flow | -$82.2M | -$70.1M | -$67.4M | -$49.4M | -$42.2M |
| Depreciation and amortization | $90.0K | $319.0K | $292.0K | $484.0K | $512.0K |
| Stock-based compensation | $13.4M | $15.6M | $25.5M | $10.8M | $8.15M |
| Investing cash flow | -$298.0M | -$12.4M | -$38.0M | -$22.3M | -$119.7M |
| Financing cash flow | $743.5M | $164.0M | $42.0M | $167.1M | $134.4M |
| Net change in cash | $363.3M | $81.5M | -$63.3M | $95.5M | -$27.2M |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | – | – | – | 814.6% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Apr 17, 2026 | 115.5M | +32.3% | SEC |
| Mar 27, 2026 | 115.4M | +32.2% | SEC |
| Nov 6, 2025 | 90.1M | +6.1% | SEC |
| Aug 1, 2025 | 87.5M | +24.4% | SEC |
| May 2, 2025 | 87.3M | +35.0% | SEC |
| Mar 14, 2025 | 87.3M | +35.0% | SEC |
| Nov 8, 2024 | 84.9M | +37.5% | SEC |
| Jul 26, 2024 | 70.4M | +15.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.